EyePoint Pharmaceuticals Inc. buy JPMorgan Chase & Co.
Start price
22.01.24
/
50%
€21.60
Target price
22.01.25
€32.12
Performance (%)
-47.55%
Price
13.05.24
€11.33
Summary
This prediction is currently active. The BUY prediction by JPMorgan_Chase___Co_ for EyePoint Pharmaceuticals Inc. is performing very badly with a performance of -47.55%. This prediction currently runs until 22.01.25. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
EyePoint Pharmaceuticals Inc. | 2.720% | 2.720% |
iShares Core DAX® | 1.662% | 4.835% |
iShares Nasdaq 100 | 0.667% | 0.000% |
iShares Nikkei 225® | -2.139% | -4.786% |
iShares S&P 500 | 0.564% | 0.775% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread EyePoint Pharmaceuticals Inc. diskutieren
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $35.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat